Welcome to our dedicated page for LifeMD 8.875% Series A Cumulative Perpetual Preferred Stock news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on LifeMD 8.875% Series A Cumulative Perpetual Preferred Stock stock.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (symbol: LFMDP) is backed by a company that offers a comprehensive telemedicine solution connecting physicians, medical providers, pharmacists, and patients worldwide. Their platform is HIPAA-compliant and encrypted, allowing for secure interactions and management of medical conditions. In addition to telehealth services, they also provide mobile diagnostic telehealth equipment and sell nutritional supplements and over-the-counter products. With a focus on virtual primary care, LifeMD is committed to providing accessible, high-quality healthcare services.
Rhea-AI Summary
LifeMD, Inc. (Nasdaq: LFMD) will be participating in several investor and industry conferences in May, including the BTIG Obesity Health Forum, Citizens JMP Securities Life Sciences Conference, and Obesity+Health Conference. Management will present corporate overviews, participate in panels, and hold one-on-one meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) declares a cash dividend for its Series A Preferred Stock, offering $0.5546875 per share to holders, payable on April 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) to participate in the 23rd Annual Needham Virtual Healthcare Conference, presenting corporate overview and meeting investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
Rhea-AI Summary
LifeMD, Inc. (LFMD) reports impressive financial results for Q4 2023 with a 60% revenue increase to $44.9 million and adjusted EPS of $0.15 per share. Telehealth revenues surged 90%, and Weight Management subscribers exceeded 22,000. The company experienced record growth in telehealth and profitability, leading to an adjusted EBITDA of $5.5 million. LifeMD raised its 2024 revenue guidance to at least $200 million, indicating a 31% growth. The company is well-positioned for expansion and aims to maintain its market disruption in telemedicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) will announce financial results for Q4 and full year 2023 on March 11, 2024. The conference call will be held at 4:30 p.m. Eastern time. Investors can dial in to listen to the call or access the webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) announced participation in multiple investor conferences and a webinar to discuss GLP-1s. CEO Justin Schreiber will be presenting at various events to engage with investors and analysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
Rhea-AI Summary
LifeMD, Inc. (LFMD) will participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024, at the Cliff Lodge in Snowbird, Utah. The company will hold one-on-one meetings during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) will participate in the Maxim Group 2024 Healthcare IT Virtual Conference on January 24-25, 2024. The company's management will engage in a virtual fireside chat and one-on-one meetings, offering investors an opportunity to engage with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) expects revenue between $195 and $205 million, a 31% to 38% increase over 2023 guidance. Adjusted EBITDA is expected to be between $18 and $22 million, a 71% to 110% increase over the midpoint of 2023 guidance. The company also anticipates positive full-year free cash flow with estimated year-end 2023 cash exceeding $30 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
Rhea-AI Summary
LifeMD, Inc. (Nasdaq: LFMD) authorizes a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP), payable on January 15, 2024, to holders of record on January 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of LifeMD 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP)?
The current stock price of LifeMD 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) is $22.75 as of January 10, 2025.
What does LifeMD, Inc. offer?
LifeMD offers a comprehensive telemedicine solution connecting physicians, medical providers, pharmacists, and patients worldwide.
Is LifeMD's platform secure?
Yes, LifeMD's platform is HIPAA-compliant and all interactions are encrypted for security.
What products does LifeMD sell?
In addition to telehealth services, LifeMD sells nutritional supplements and over-the-counter products.
What is the focus of LifeMD's services?
LifeMD is focused on providing virtual primary care to make high-quality healthcare accessible for all.
How does LifeMD contribute to the healthcare industry?
LifeMD's telemedicine platform and services aim to improve patient outcomes and provide more convenient access to healthcare.
LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock
Nasdaq:LFMDP
LFMDP Rankings
LFMDP Stock Data
1.40M
Health Information Services
Services-offices & Clinics of Doctors of Medicine
United States of America
NEW YORK